A facile synthesis of novel unsymmetrical N-(4-oxo-2-phenyl-3(4H)-quinazolinoyl)-N-(aryl)acetamidines

<正>A series of novel unsymmetrical N-(4-oxo-2-phenyl-3(4H)-quinazolinoyl)-N-(aryl) acetamidines was synthesized by reacting ethyl(1H)-N-(4-oxo-2-phenylquinazolin-3(4H)-y1)ethanimidoate(2) and suitable reactive aromatic amines.Structures' determination of the synthesized compounds was carried out using spectroscopic techniques including IR,~1H NMR,and mass spectrometry. Structural effects on reactivity were also studied.     

Stress degradation studies and development of stability-indicating TLC-densitometry method for determination of prednisolone acetate and chloramphenicol in their individual and combined pharmaceutical formulations

ABSTRACT: A rapid and reproducible stability indicating TLC method was developed for the determination of prednisolone acetate and chloramphenicol in presence of their degraded products. Uniform degradation conditions were maintained by refluxing sixteen reaction mixtures for two hours at 80°C using parallel synthesizer including acidic, alkaline and neutral hydrolysis, oxidation and wet heating degradation. Oxidation at room temperature, photochemical and dry heating degradation studies were also carried out. Separation was done on TLC glass plates, pre-coated with silica gel 60F-254 using chloroform: methanol (14:1 v/v). Spots at Rf 0.21 ± 0.02 and Rf 0.41 ± 0.03 were recognized as chloramphenicol and prednisolone acetate, respectively. Quantitative analysis was done through densitometric measurements at multiwavelength (243 nm, λmax of prednisolone acetate and 278 nm, λmax of chloramphenicol), simultaneously. The developed method was optimized and validated as per ICH guidelines. Method was found linear over the concentration range of 200-6000 ng/spot with the correlation coefficient (r2 ± S.D.) of 0.9976 ± 3.5 and 0.9920 ± 2.5 for prednisolone acetate and chloramphenicol, respectively. The developed TLC method can be applied for routine analysis of prednisolone acetate and chloramphenicol in presence of their degraded products in their individual and combined pharmaceutical formulations.     

Meliloester, a new melilotic ester from Melilotus alba

A new melilotic ester, meliloester [2-ethyl-hexyl-3-(2-hydroxyphenyl) propionate], was isolated from the whole plant of Melilotus alba. Its structure was elucidated on the basis of spectroscopic and mass spectrometric analyses, including EI-MS, HR-MS, and UV, IR, 1D and 2D-NMR spectroscopic studies.     

Microbial transformation of oleanolic acid by Fusarium lini and alpha-glucosidase inhibitory activity of its transformed products

The biotransformation of a pentacyclic triterpene, oleanolic acid (1), with Fusarium lini afforded two oxidative metabolites, 2alpha,3beta-dihydroxyolean-12-en-28-oic acid (2), and 2alpha,3beta,11beta-trihydroxyolean-12-en-28-oic acid (3). Metabolite 3 was found to be a new compound. The structures were characterized on the basis of spectroscopic studies. These metabolites exhibited a potent inhibition of alpha-glucosidase enzyme.     

Iron salts catalyzed synthesis of β-N-substituted aminoacrylates

The direct condensation of amines with β-ketoesters to produce functional enamine derivatives has been investigated with iron Lewis acid catalysts. FeCl₃·6H₂O shows good catalytic activity and makes possible the chemo- and stereoselective formations of (Z)-enamine derivatives from aliphatic and aromatic primary amines under mild conditions.     

Validated Method for the Simultaneous Determination of Gemifloxacin and H2‐receptor Antagonists in Bulk,Pharmaceutical Formulations and Human Serum by RP‐HPLC; In‐vitro Applications

Simple, isocratic and rapid RP‐HPLC method has been developed for the simultaneous analysis of gemifloxacin and H₂‐receptor antagonists i.e. Cimetidine, Famotidine and Ranitidine, in bulk, pharmaceutical formulation and human serum. Separation was achieved on the RP‐Mediterranea column [C18 (250 × 4.6 mm, 5 μ)] at ambient temperature using mobile phase consisting of acetonitrile: methanol: water (20:28:52 v/v/v pH 2.8 adjusted by phosphoric acid). Flow rate was 1.0 mL/min with an average operating pressure of 180 kg/cm². Gatifloxacin (GATI) was used as an internal standard (IS). Quantitation was achieved with UV detection at 221, 256 and 267 nm, respectively. Linear calibration curves, at concentration ranges of 0.05‐37.5 μgmL^‐L with a correlation coefficient of ±0.9994. The detection and quantification limits were in the ranges of 0.023‐0.250 μgmL^‐L and 0.071‐0.756 μgmL^‐L, respectively. Friedman's and Student's t‐test were applied to correlate these results. Method was validated in terms of selectivity, linearity, precision, robustness, recovery, limits of detection and quantitation and is applicable to the routine analysis of GFX and H₂‐receptor antagonists, alone or in combination.     

Development and Validation of a Liquid Chromatographic Method for the Determination of Leflunomide: Application to in vitro Drug Metal Interactions

Leflunomide is a leading drug for the treatment of rheumatoid arthritis. The principle aim of this study was to develop and validate an RP‐HPLC method for the determination of leflunomide in bulk and pharmaceutical dosage form using diclofenac sodium as an internal standard. For this purpose, chromatography was accomplished on a Purospher Start, C₁₈ (5 (m, 12.5 cm×0.46 cm) column at ambient temperature. Methanol:water (80:20, V/V) solvent system was selected as mobile phase, the pH of which was adjusted to 3.4 by ortho‐phosphoric acid and delivered at a flow rate of 1.2 mL·min⁻¹. Seperation of leflunomide and diclofenac sodium was carried out on a Purospher Start, C₁₈ equipped with a UV‐visible detector at 248 nm. The suitability of the method for the quantitative determination of the drugs is proven by validation in accordance with the requirements laid down by the International Conference on Harmonization (ICH) guidelines. The method was accurate (99.55%–100.03%), specific, linear (R²>0.999) and precise (intra‐day precision 0.023%–0.93% and inter‐day precision 0.26%–0.944%) in the range of 0.5–20 (g·mL⁻¹. The minimum limit of detection and quantification in pharmaceutical formulation were 0.05 and 0.15 (g·mL⁻¹, respectively. Thus the proposed method is simple, accurate, reproducible and suitable for the routine analysis of leflunomide in pharmaceutical formulations and was applied to study in vitro drug‐metal interactions.     

A study of redox properties of hydralazine hydrochloride,an antihypertensive drug

Hydralazine hydrochloride itself is a reducing agent and its redox properties like other reducing agents vary as the oxidizing agent and applied conditions vary. The redox properties of hydralazine were studied by spectrophotometric method. Formal redox potential of hydralazine was calculated and effect of pH was observed on redox properties of hydralazine.     

High-performance Liquid Chromatographic Analysis of Pioglitazone,Gliquidone,Rosuvastatin and Simvastatin in Formulations and Human Serum

Co‐administration of HMG‐CoA reductase with antidiabetic drugs is most common since antidiabetic drugs are mostly prescribed for long term therapy. In the present paper, we describe the simultaneous determination of antidiabetic (pioglitazone hydrochloride and gliquidone) in presence of statins (rosvastatin and simvastatin) in formulations and in human serum using RP‐HPLC technique. The serum samples were subjected to protein precipitation with acetonitrile prior to an HPLC analysis. At a flow rate of 1 mL·min⁻¹ isocratic elution was employed, using mobile phase consisting of methanol/water (90:10, V:V), pH 3.50 with phosphoric acid and absorbance was recorded at 235 nm. The assay was reproducible, linear (concentration range of 5–50 μg·mL⁻¹) and accurate. The LOD and LOQ values were 1.32, 0.28, 0.05 and 0.57 μg·mL⁻¹ and 4.39, 0.93, 0.16 and 1.90 μg·mL⁻¹ for pioglitazone hydrochloride, gliquidone, rosvastatin and simvastatin, respectively. There were no interfering peaks due to the excipients present in the pharmaceutical tablet and serum. Thus, the proposed method is simple and suitable for the analysis of active ingredient in tablet form and human serum.